SLP Earnings

SLP reported its FY2025Q4 earnings on 2025-12-01, showcasing a revenue of 17.50M against an estimate of 17.39M, resulting in a 0.64% surprise. The EPS was 0.1, surpassing the expected 0.1 by 0%. The stock experienced a 14.14% price change on the earnings day and a 14.79% change over the next five days, reflecting market reactions to the results.

Following SLP's FY2025Q4 earnings announcement on 2025-12-01, the stock price moved by 14.14% on the day of the release. Over the subsequent five days, it saw a 14.79% change. Historically, SLP's stock price tends to shift by an average of 0.12% in the 10 days leading up to earnings and 4.14% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate SLP's annual revenue to reach 21.66M, while the EPS is projected at 0.20. These estimates reflect recent revisions, with revenue estimates revised upward by 0.43% and EPS estimates revised downward by -1.09% over the past three months, indicating analyst expectation in the company's performance.

The correlation between SLP's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2026 were revised upward by 0.43%, while EPS estimates moved revised downward by -1.09%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, SLP's stock price typically moves by 0.12% in the 10 days before its earnings and 4.14% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of 0.20 and revenue of 21.66M.

The earnings call summary presents a mixed outlook. While there is positive news about software performance peaking and MedCom exceeding expectations, challenges exist with clinical operations software revenue and tough comparisons. The Q&A section reveals cautious optimism with no change in guidance and AI integration showing promise. However, management's avoidance of specific details and the lack of new verticals or products in the near term suggest limited immediate catalysts. Consequently, the stock is likely to remain neutral over the next two weeks.